more

Bio-Path Holdings (BPTH)

(Real Time Quote from BATS)

$2.61 USD

-0.08 (-2.79%)

Updated Apr 24, 2024 01:44 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank	Definition	Annualized Return
1	Strong Buy	24.20%
2	Buy	18.04%
3	Hold	9.52%
4	Sell	5.20%
5	Strong Sell	2.60%
S&P	500	11.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5 3

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score	A
Growth Score	A
Momentum Score	A
VGM Score	A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value B Growth A Momentum C VGM

Industry Rank:

Bottom 42% (147 out of 252)

Industry: Medical - Drugs

View All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Bio-Path (BPTH) Rises on Upbeat Updates From Blood Cancer Study

by Zacks Equity Research Published on April 19,2024

Bio-Path (BPTH) gains 30% on encouraging developmental updates from the early-stage study of its investigational candidate, BP1002, to treat acute myeloid leukemia patients.

Amneal (AMRX) Parkinson's Candidate Successful in Pivotal Study

by Zacks Equity Research Published on August 26,2021

Amneal's (AMRX) IPX-203 increases "Good On" time by 1.55 hours per dose versus immediate-release CD/LD in patients with Parkinson's disease.

pharmaceuticals

Bio-Path (BPTH) to Begin Clinical Study on Leukemia Drug

by Zacks Equity Research Published on August 25,2021

Bio-Path Holdings' (BPTH) IND application for BP1002 receives clearance from the FDA. It is set to begin a phase I/Ib study for treating AML patients. The stock rises following the announcement.

Bio-Path (BPTH) Moves to Buy: Rationale Behind the Upgrade

by Zacks Equity Research Published on March 16,2021

Bio-Path (BPTH) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

BPTHNegative Net Change

Radius Completes Enrollment in Phase III Osteoporosis Study

by Zacks Equity Research Published on September 09,2020

Radius (RDUS) completes enrollment in its phase III study assessing a wearable abaloparatide-transdermal patch in the treatment of postmenopausal women with osteoporosis at high risk for fracture.

pharmaceuticals

Onconova's Cancer Study Fails to Meet Endpoint, Shares Down

by Zacks Equity Research Published on August 25,2020

Onconova's (ONTX) shares fall more than 60% after its phase III study on intravenous rigosertib in patients with higher-risk myelodysplastic syndromes did not meet the primary endpoint.

pharmaceuticals

Bio-Path (BPTH) Upgraded to Buy: Here's Why

by Zacks Equity Research Published on August 20,2020

Bio-Path (BPTH) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

BPTHNegative Net Change

Zacks.com featured highlights include: Denny's, Heico, Oasis Midstream Partners, NV5 Global and Bio-Path

by Zacks Equity Research Published on January 23,2020

Zacks.com featured highlights include: Denny's, Heico, Oasis Midstream Partners, NV5 Global and Bio-Path

oil-energy

Bio-Path (BPTH) Upgraded to Buy: Here's What You Should Know

by Zacks Equity Research Published on December 04,2019

Bio-Path (BPTH) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

BPTHNegative Net Change

Bio-Path Leukemia Combo Study Shows Positive Early Data

by Zacks Equity Research Published on April 04,2018

Bio-Path (BPTH) announces positive interim data from phase II study of its lead pipeline candidate ??? prexigebersen ??? in combination with low-dose cytarabine (LDAC) for leukemia patients.